This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Earnings Season Could Be Great for Nuvalent (NUVL)
by Zacks Equity Research
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
by Zacks Equity Research
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
by Zacks Equity Research
Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going
by Zacks Equity Research
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.